- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00964730
A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm
April 6, 2010 updated by: Teva Branded Pharmaceutical Products R&D, Inc.
A Phase I, Single-Center, Double-Blind, Randomized, Placebo- and Positive- Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Talampanel on Cardiac Repolarization in Healthy Male and Female Volunteers
The purpose of this study is to assess whether multiple doses of Talampanel increase the QT interval when compared to placebo
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
135
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Dakota
-
Fargo, North Dakota, United States, 58104
- Cetero Research - Fargo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy volunteers aged 18 to 50 years of age inclusive.
- Body mass index: Between 18 and 30 kg/m2 and weight of at least 50 kg.
- Female volunteers must have either a negative pregnancy test and be willing to use birth control, be post-menopausal evidenced by lab test, or be surgically sterile.
- Volunteers must be able to understand the requirements of the study and must be willing to comply with the requirements of the study and provide their written informed consents to participate in the study prior to the conduct of study procedures.
Exclusion Criteria:
- Male and female volunteers with a resting QT interval of < 320 msec or > 450 msec (males) or > 470 msec (females
- Volunteers with ECG abnormalities that may interfere with the accurate assessment of the QT interval
- Volunteers with known cardiovascular disorders, including coronary artery disease, valvular heart disease, cardiomyopathies, or ECG abnormalities suggestive of prior myocardial infarction, chamber enlargement or hypertrophy.
- Volunteers with known clinically significant arrhythmias or rhythm disturbances observed on ECG
- Volunteers who have a history of, or risk factors for, Torsades de Pointes (e.g. heart failure, abnormal serum electrolytes), including a history of family history of arrhythmia, sudden death, long QT syndrome, Brugada complex, or personal history of syncope.
- Volunteers who have a heart rate outside 40-90 beats per minute
- Volunteers who have a blood pressure outside 90-140 mmHg systolic or 45-90 mmHg diastolic
- Volunteers with history of uncontrolled hypertension, impaired glucose tolerance, diabetes mellitus, kidney disease, edema, stroke or neurological disorder, rheumatological disorder, lung disease, heart disease, liver disease, or a history of any illness that pose additional risk to the volunteer
- Volunteers with a history of psychiatric disorders, including bipolar disorder, psychosis, previous episode(s) of major depression, history of suicidality or suicidal ideation.
- Volunteers who have history of surgeries or conditions that affect the way drugs are absorbed or distributed in the body such as intestinal surgery, stomach surgery.
- Volunteers with impaired liver function and elevated liver enzymes
- Volunteers with major trauma or surgery in the past 2 months, acute infection within 2 weeks, cancer within the last 5 years (excluding non-melanoma skin cancers), History of tuberculosis, abnormal lab tests
- Female volunteers who are lactating or intend to become pregnant during the study period.
- Volunteers with a known allergy or sensitivity to moxifloxacin or its derivatives, benzodiazepines, talampanel or its derivatives, or any contraindications to moxifloxacin, benzodiazepines, or talampanel.
- Volunteers with significant food or drug allergies
- Volunteers that have used an investigational drug (new chemical entity) 3 months prior to the start of the study,.who have consumed any medications (including over-the-counter medications, prescription medications, investigational drugs, vitamins, or herbal remedies) within 30 days prior to check-in (with the exception of hormonal contraceptives [females only] and occasional use of acetaminophen and ibuprofens, who have consumed amiodarone and chloroquine within 4 months prior to screening, who have consumed excessive amounts of alcohol or are unwilling to comply with the restricted use of alcohol during the study, who have consumed excessive amounts of coffee, tea, coke, or other caffeinated beverages within 2 weeks prior to check-in, who have consumed quinine (tonic water) within 7 days prior to study start, who have consumed grapefruit, grapefruit juice, or Seville orange juice within the 7 days prior to study start, who smoke, have smoked in the last 3 months, or are planning to start smoking during the study, tobacco users, subjects currently using nicotine products, or subjects with a positive urine cotinine test at study start
- Volunteers who are currently regular users (including recreational use) of any illicit drugs or who have a history of drug (including alcohol) abuse within 1 year of study start.
- Volunteers with positive urine test for drugs of abuse at screening or check-in.
- Volunteers who have donated or received any blood, plasma, or platelet transfusions in the 3 months prior to study start, or who have made donations on more than two occasions within the 12 months preceding the first dose administration, or who have planned donations during the study or during the 3 months following the study.
- Volunteers with a positive screening test for Hepatitis B, Hepatitis C or HIV
- Volunteers not willing to refrain from changing level of activity during the study and from jogging and strenuous exercise of all types while at the research unit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
administered three times a day over 9 days and a single dose administered on Day 10
|
EXPERIMENTAL: Talampanel
|
titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
Other Names:
|
OTHER: Moxifloxacin
|
Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the effects of Talampanel on cardiac repolarization after multiple therapeutic doses administered over 10 days
Time Frame: 12 days
|
12 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Examine the PK profile of talampanel and its metabolite -Assess the PK/PD relationship of the time course of QT/QTc interval prolongation-Assess the safety and tolerability of multiple doses of talampanel in healthy volunteers
Time Frame: 12 days
|
12 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Craig R Sprenger, MD, Cetero Research - Fargo
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (ACTUAL)
January 1, 2010
Study Completion (ACTUAL)
February 1, 2010
Study Registration Dates
First Submitted
August 21, 2009
First Submitted That Met QC Criteria
August 24, 2009
First Posted (ESTIMATE)
August 25, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
April 7, 2010
Last Update Submitted That Met QC Criteria
April 6, 2010
Last Verified
April 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAL-TQT-101
- R09-0539
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Talampanel
-
National Institutes of Health Clinical Center (CC)National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CovanceTerminated
-
Teva Branded Pharmaceutical Products R&D, Inc.Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.TerminatedAmyotrophic Lateral Sclerosis
-
National Institute of Neurological Disorders and...Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.National Cancer Institute (NCI)TerminatedGlioblastoma Multiforme | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Anaplastic Mixed Oligoastrocytoma
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedParkinson Disease | Movement Disorders | Dyskinesias
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedGlioblastoma Multiforme
-
National Institute of Neurological Disorders and...Completed
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedALSUnited States, Netherlands, Canada, Italy, Spain, Belgium, France, Germany, Hungary, Israel